Medical Oncologist
Long-term treatment effects
Secondary Cancers After — Long-Term PARP Inhibitor Use
A small proportion of people on PARP inhibitors develop a bone marrow disorder called myelodysplastic syndrome over time. It is uncommon, but because early detection changes the outcome, knowing what to watch for matters more than the worry itself.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- It is a blood disorder, not a solid tumour — The main secondary cancer risk is myelodysplastic syndrome (MDS), a bone marrow condition — not a new lump or growth.
- The risk is real but uncommon — NCCN and ASCO acknowledge the risk — routine blood monitoring is exactly how it is caught early.
- Blood tests pick it up before symptoms do — Regular blood count checks during and after treatment are the primary safety net your team uses.
- Symptoms are not silent forever — Unusual fatigue, easy bruising, or repeated infections are the body's early signals — report them promptly.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
A small proportion of people on PARP inhibitors develop myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) — both blood disorders — with risk building over time. NCCN and ASCO recommend regular blood count monitoring to catch changes early. Most patients do not develop this, but new fatigue, easy bruising, or repeated infections need same-day reporting.
If a symptom below applies to you, do not wait for a callback. Call 1800-202-8726 or go to your nearest emergency department.
What is the secondary cancer risk, and how dangerous is it?
PARP inhibitors work by blocking a DNA-repair pathway that cancer cells depend on. Over time, that same mechanism can occasionally affect healthy bone marrow cells. A small proportion of patients develop myelodysplastic syndrome (MDS) or, less commonly, acute myeloid leukaemia (AML).
Both are serious conditions — but serious is not the same as untreatable. NCCN and ASCO recommend routine blood monitoring during and after PARP inhibitor treatment because early detection changes the outcome significantly.
If your blood tests have been coming back normal on your regular checks, that is the most meaningful reassurance you have. The monitoring your team has put in place is doing its job.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Which symptoms need action — and how urgently?
| What you notice | What it may mean | What to do |
|---|---|---|
| Fatigue worsening over weeks, not relieved by rest | Possible fall in red cell count | Call your oncology team today for a blood count check |
| New bruises without injury, or bruises larger than expected | Possible fall in platelet count | Call today; go to emergency if bruising is widespread or spreading fast |
| Repeated infections or infections unusually slow to clear | Possible fall in white cell count | Call today; go to emergency if you also have fever |
| Bleeding gums or nosebleeds that are new or harder to stop | Possible platelet change | Call today |
| Shortness of breath with mild activity that was not there before | Can accompany significant anaemia | Call today; go to emergency if severe or present at rest |
| Typically starts | Months to years into treatment — sometimes after stopping | Report any of the above at any point during or after PARP inhibitor treatment |
Did you know?
Therapy-related blood disorders after cancer treatment are not unique to PARP inhibitors — they are a recognised risk across several treatment classes, including certain chemotherapy agents.
ASCO, ESMO, and NCCN group them under therapy-related myeloid neoplasms and recommend the same approach: regular monitoring, prompt reporting, and specialist assessment if blood counts shift.
Source: ASCO and ESMO clinical practice guidelines on therapy-related myeloid neoplasms; NCCN Guidelines for Myelodysplastic Syndromes
What else should you know about long-term PARP inhibitor risk?
How likely am I to develop MDS or AML on a PARP inhibitor?
The risk is recognised but uncommon, and NCCN and ASCO both treat it as a surveillance question rather than a reason to avoid treatment where it is indicated. There is no single reliable percentage that applies to every patient — the risk varies with how long treatment has continued, whether you had prior chemotherapy, and your individual cancer biology. Your oncologist can explain where you sit relative to those factors. Most people on PARP inhibitors do not develop a blood disorder, and routine blood tests are how your team will catch it early if it begins.
How often should my blood be checked while I am on a PARP inhibitor?
NCCN guidance recommends complete blood count monitoring throughout PARP inhibitor treatment, with the frequency determined by your oncologist based on your individual situation and how long you have been on treatment. If you are unsure when your next blood test is due or whether you have missed one, that is worth asking at your next appointment — or calling to confirm before then. Do not assume that because you feel well, the monitoring can wait.
Can I do anything to reduce the risk?
There is no lifestyle change that eliminates this risk. Be cautious about supplements or herbal products that claim to protect the bone marrow — none have evidence behind them in this context, and some interact with cancer treatment. What you can do is keep all scheduled blood tests, report new symptoms promptly, and tell your team about everything you are taking. Missing a monitoring blood count is the one thing most directly in your control, and it matters.
What happens if my blood test shows a change?
If a blood count result falls outside expected limits, your oncologist will first decide whether it is related to the PARP inhibitor or another cause. They may increase monitoring frequency, order a bone marrow biopsy to examine the marrow directly, or hold the PARP inhibitor while the picture is clarified. A single abnormal result is not a diagnosis — it is a prompt for a closer look. Your team will explain the next steps based on what the result shows.
Should I stop my PARP inhibitor because of this risk?
That decision should be made with your oncologist, not in response to something you have read. PARP inhibitors are used because, for the cancers where they are indicated, they are expected to provide meaningful benefit. Stopping prematurely means losing that benefit. The risk of a secondary blood disorder is a reason for careful monitoring, not a reason to stop treatment without medical review. Bring this question directly to your next appointment so it can be discussed in the context of your own results and situation.
Explore 108 more Side Effects, Emergencies & Daily Living topics
Side Effects - Symptom-Specific Deep Dives
- Abdominal Pain on Targeted Therapy: When to Worry
- Acne-Like Rash on EGFR Inhibitors: Why It Happens and How to Treat It
- Anaemia and Low Haemoglobin During Targeted Therapy
- Blood Clots and Stroke Risk on Targeted Therapy
- Blurred Vision and Eye Problems on Cancer Drugs
- Brain Fog and Memory Problems During Treatment
- Breathlessness and Cough on Targeted Therapy: Ruling Out ILD
- Constipation During Targeted Therapy
- Diarrhoea on Targeted Therapy: How to Control It at Home
- Dry Eyes and Light Sensitivity During Treatment
- Extreme Fatigue on Targeted Therapy: Causes and What Helps
- Extremely Dry, Cracking Skin on Cancer Tablets
- Fever During Targeted Therapy: Home Care vs Emergency
- Hair Thinning, Curling and Colour Change on Targeted Therapy
- Hand-Foot Skin Reaction: Prevention and Relief
- Headaches and Dizziness on Targeted Therapy
- Heart Function Drop (Low Ejection Fraction) on Targeted Therapy
- High Blood Pressure Caused by Cancer Drugs
- High Blood Sugar on PI3K and mTOR Inhibitors
- Infusion Reactions: What Happens and How They're Managed
- Interstitial Lung Disease (ILD): The Side Effect You Must Not Ignore
- Itching That Won't Stop on Targeted Therapy
- Kidney Function Changes on Targeted Therapy
- Loss of Appetite and Weight Loss During Targeted Therapy
- Low Magnesium and Electrolyte Problems on Anti-EGFR Antibodies
- Low Platelets on PARP Inhibitors and TKIs
- Low White Cells and Infection Risk on Targeted Therapy
- Mouth Ulcers and Mucositis: Practical Relief
- Muscle Cramps and Joint Pain on Cancer Drugs
- Nausea and Vomiting on Oral Cancer Drugs
- Osteonecrosis of the Jaw: Prevention During Bone-Targeted Treatment
- Paronychia and Nail Changes on Targeted Therapy
- Peripheral Neuropathy: Tingling and Numbness in Hands and Feet
- Protein in Urine (Proteinuria) During Treatment
- QT Prolongation: What It Means on Your ECG Report
- Raised Liver Enzymes (SGPT/SGOT) on Targeted Therapy
- Secondary Cancers After Long-Term PARP Inhibitor Use
- Severe Rash With Fever or Blistering: A Medical Emergency
- Skin Darkening, Depigmentation and Pigment Changes
- Slow Heart Rate and Dizziness on Certain TKIs
- Sun Sensitivity and Photosensitivity on Cancer Drugs
- Swallowing Difficulty and Reflux on Cancer Tablets
- Swelling of Face, Legs and Around the Eyes
- Taste Changes and Metallic Mouth on Cancer Drugs
- Tumour Lysis Syndrome: A Rare but Serious Early Complication
- Underactive Thyroid (Hypothyroidism) Caused by Cancer Drugs
- Unusual Bleeding or Bruising on Cancer Drugs
- Voice Changes and Hoarseness on Targeted Therapy
- Weight Gain During Long-Term Targeted Therapy
- When Diarrhoea Becomes an Emergency: The Rule You Must Know
- Wound Healing Problems on Antiangiogenic Drugs
Daily Living & Adherence
- Can I Drink Alcohol on Targeted Therapy?
- Can I Drive While on Targeted Therapy?
- Can I Fast for Religious Reasons During Targeted Therapy?
- Can I Have Dental Treatment While on Targeted Therapy?
- Exercise During Targeted Therapy: How Much Is Safe?
- Haircuts, Waxing, Facials and Tattoos During Treatment
- How Should Family Members Handle Your Cancer Tablets Safely?
- I Accidentally Took a Double Dose: How Serious Is It?
- I Missed a Dose of My Targeted Therapy: What Should I Do?
- I Vomited Right After Taking My Tablet: Do I Repeat the Dose?
- Managing a Household Routine Around Your Dosing Schedule
- Pets, Gardening and Infection Precautions
- Running Out of Medicine: What to Do About Refills and Shortages
- Safe Disposal of Unused Cancer Medicines
- Sex and Intimacy While on Targeted Therapy: Safety Questions
- Sleep Problems on Targeted Therapy and What Actually Helps
- Smoking and Targeted Therapy: How It Changes Your Drug Levels
- Travelling With Cancer Tablets: Flights, Security and Storage
Emergency & Red-Flag Triage
- Chest Pain or Palpitations During Cancer Treatment
- Emergency Contact Card: What to Keep in Your Wallet
- Fever Above 100.4F on Cancer Treatment: The 1-Hour Rule
- Heavy Bleeding, Blood in Vomit or Black Stools
- Not Passing Urine or Sudden Swelling All Over
- Severe Rash Spreading Rapidly With Mouth or Eye Involvement
- Sudden Breathlessness on Cancer Tablets: Go to Emergency or Wait?
- Sudden Confusion, Seizure or Weakness on One Side
- Sudden Severe Abdominal Pain: Ruling Out Perforation
- Sudden Vision Loss or Double Vision: What to Do Right Now
- Swollen, Painful Leg: Recognising a Blood Clot
- Uncontrolled Diarrhoea: The 6-Stool Rule Every Patient Should Know
- What to Tell an ER Doctor Who Doesn't Know Your Cancer Drug
- Yellow Eyes, Dark Urine or Severe Right-Sided Pain
Food, Drug & Supplement Interactions
- Antacids and Acidity Tablets Can Block Your Cancer Drug
- Anti-Nausea and Anti-Acidity Drugs That Prolong QT
- Anti-TB Treatment and Targeted Therapy: A Dangerous Combination
- Antibiotics and Antifungals That Interfere With Cancer Drugs
- Ayurvedic and Herbal Medicines With Targeted Therapy: The Real Risks
- Blood Thinners and Targeted Therapy: Managing the Bleeding Risk
- Contraceptive Pills and Hormone Medicines With Cancer Drugs
- Diabetes and Blood Pressure Medicines With Targeted Therapy
- Grapefruit, Pomegranate and Starfruit: Why They're Banned on Many Cancer Drugs
- Green Tea, Coffee and Caffeine on Targeted Therapy
- Homeopathy Alongside Targeted Therapy: What You Should Know
- How to Check Any New Medicine Against Your Cancer Drug
- Painkillers: Which Ones Are Safe on Targeted Therapy?
- Protein Powders and Immunity Boosters: Helpful or Harmful?
- Statins and Cholesterol Medicines During Cancer Treatment
- The Complete Do-Not-Take List for Common Targeted Therapy Drugs
- Turmeric, Ashwagandha, Giloy and Wheatgrass During Cancer Treatment
- Vaccines and Antivirals During Targeted Therapy
- Vitamin, Calcium and Iron Supplements During Treatment
Side Effects - General & Timeline
- Are Side Effects a Sign That the Drug Is Working?
- Side Effect Timeline: What Happens in Week 1, Month 1 and Month 6
- Targeted Therapy Side Effects: The Complete List by Drug Class
- Understanding Side Effect Grades 1 to 4 (In Plain Language)
- When to Call Your Oncologist Immediately: The Red Flag List
- Will a Dose Reduction Make My Treatment Less Effective?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is secondary cancer from a PARP inhibitor common?
No. The risk of myelodysplastic syndrome or AML is recognised in NCCN and ASCO guidance, but it is uncommon rather than expected. Most people on PARP inhibitors do not develop a blood disorder. The risk is the reason for routine blood monitoring — if counts change, early detection matters. What your individual risk looks like depends on factors your oncologist can discuss with you, including treatment duration and prior chemotherapy.
What is MDS, and how is it different from AML?
Both are disorders of the bone marrow, where blood cells are made. Myelodysplastic syndrome (MDS) means the marrow is producing abnormal cells that do not function properly — it can remain stable or progress over time. Acute myeloid leukaemia (AML) develops more rapidly. Therapy-related MDS and AML — meaning those that develop after cancer treatment — are the forms associated with PARP inhibitors. Both are assessed by a haematologist, often with a bone marrow biopsy.
Can MDS or AML after a PARP inhibitor be treated?
Yes. Treatment options exist for therapy-related MDS and AML. The approach depends on which condition is present, how severe it is, your age and fitness, and other individual factors. These decisions are made by a haematologist in a multidisciplinary team. We do not yet have complete long-term data for every situation, and your team will be honest about what is known and what remains uncertain for your specific case.
My PARP inhibitor was stopped months ago — am I still at risk?
Yes, and monitoring does not stop when the drug does. Therapy-related blood disorders can develop months to years after the treatment that contributed to them. ASCO and ESMO guidance covers surveillance after stopping, not only during active treatment. If you have had no follow-up blood count since stopping, ask your team when the next one is due. New fatigue, bruising, or repeated infections deserve a call at any point — not only while you are on the drug.
How do I know if my fatigue is a sign of MDS or just ordinary tiredness?
You cannot tell from the feeling alone, and neither can your doctor without a blood test. What matters is the pattern: fatigue that is new, worsening over weeks, and not explained by poor sleep or other factors you can identify is the kind worth reporting. Do not try to grade it as significant or not on your own — call your oncology team and describe what you are noticing, including when it started and whether anything makes it better or worse. A blood count can usually give a clear answer quickly.